Eli Lilly and : Pfizer, Eli Lilly Report Unfavorable FDA Advisory Panel Vote for Tanezumab

By Josh Beckerman

Pfizer Inc. and Eli Lilly & Co. announced an unfavorable vote from a joint U.S. Food and Drug Administration advisory committee on tanezumab for osteoarthritis pain.

The companies said the vote was one in favor and 19 against on the question of whether the proposed risk evaluation and mitigation strategy would ensure benefits outweigh risks.

Pfizer and Lilly said, "While we are disappointed with today's outcome, we continue to believe that tanezumab has a positive benefit-risk profile for patients with moderate-to-severe osteoarthritis pain for whom current treatments are ineffective or not appropriate."

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

03-25-21 1621ET